Alexion Pharmaceuticals, Inc. · 1 week ago
Associate Director, Translational Research Hematology R&D
Waltham, Massachusetts, United States of America
Full-time
Hybrid
Lead/Staff, Director/Executive
$135K/yr - $202K/yr
5+ years expAstraZeneca is a global, science-led, patient-focused biopharmaceutical company dedicated to advancing the science to deliver life-changing medicines to patients. The Associate Director will lead a team in developing translational assays and executing critical experiments that support the Hematology Translational Medicine Department’s strategy, focusing on multiple myeloma and blood cancer precursor conditions.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
The AD is responsible for the design and execution of non-clinical and translational experiments to understand hematological tumor biology, supporting the AZ portfolio. This work includes, but is not limited to, testing target expression after treatment, novel MRD technologies, reverse translation approaches to identify mechanisms of resistance, and informing new combinations across multiple heme indications
This role will lead translational assay development supporting programs in multiple myeloma and blood cancer precursor conditions, as well as other heme malignancies indications
Integrate Translational Medicine Research Scientists with broader drug development teams, including translational medicine (TM leads, data scientists, etc.), discovery, and clinical groups
Manage a team of lab-based scientists to support Hematology Translational Medicine research efforts
Apply literature reviews, protocols, networking and prior laboratory experience to advance clinical and pre-clinical aims of the Hematology Translational Medicine group
Demonstrate excellent organizational and communication skills for cross-functional interactions
Writes research papers, abstracts, technical reports, regulatory documents and SOPs
Performs all duties in compliance with internal SOPs and external regulations
Qualification
Required
Doctorate degree in immunology, molecular biology or related field with experience in hematology-oncology
Minimum of 5 years of industry experience including managerial experience of junior scientists and technicians
Strong background in oncology, cell biology, immunology, and small molecule drug discovery, ADCs, cell therapies or TCEs
Strong hands-on experience with translational lab methodologies applicable to biomarker studies in pre-clinical models and clinical trials (eg. NGS, flow cytometry, qPCR, etc) including data analysis of large datasets
Collaborating with clinical teams and working with clinical trial samples including for e.g. peripheral blood and bone marrow. Knowledge of clinical protocol design and biospecimen logistics
Robust track record of scientific achievement, and innovation approaches as evidenced by publication record
Excellent interpersonal skills, ability to work as an integral member of a team, and proficiency in training and managing a team
Strong written and oral communication skills
Proven excellence in designing, executing, and interpreting cancer biomarker studies in preclinical models and clinical trials, including biomarker development, validation, and clinical application
Benefits
Eligibility for various incentives
Short-term incentive bonuses
Equity-based awards for salaried roles
Commissions for sales roles
Qualified retirement programs
Paid time off (i.e., vacation, holiday, and leaves)
Health, dental, and vision coverage
Company
Alexion Pharmaceuticals, Inc.
Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community.
1001-5000 employees
H1B Sponsorship
Alexion Pharmaceuticals, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (49)
2024 (57)
2023 (51)
2022 (29)
2021 (27)
2020 (17)
Funding
Current Stage
Public CompanyTotal Funding
$5.8M2020-12-12Acquired
1999-02-12Post Ipo Equity· $5.8M
1996-02-29IPO
Leadership Team
Frederic Chereau
SVP, Strategy and Business Development
Imran Shakur
Director, IRT and Technology Lead
Recent News
bloomberglaw.com
2025-12-20
Company data provided by crunchbase